Collaboration for Cancer Outcomes, Research and Evaluation, Ingham Institute for Applied Medical Research, South Western Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
GenesisCare, Sydney, New South Wales, Australia.
J Med Imaging Radiat Oncol. 2022 Mar;66(2):233-241. doi: 10.1111/1754-9485.13372.
The adoption of hypofractionation across multiple tumour sites has been slow despite robust evidence. There is considerable unwarranted variation in practice, both within and between jurisdictions. This has been attributed to inconsistencies in guidelines, physician preference, lack of technology and differing financial incentives. Unwarranted variation in the use of hypofractionation has a tremendous effect on cost to both patients and the healthcare system. This places an unnecessary burden on patients and poorly utilises scarce healthcare resources. A collaborative effort from clinicians, patients, healthcare providers and policymakers is needed to reduce unwarranted variation in practice. This will improve quality of care both for patients and at broader healthcare system level.
尽管有强有力的证据，但在多个肿瘤部位采用低分割放疗的速度仍然缓慢。在实践中，无论是在司法管辖区内还是之间，都存在着大量不必要的差异。这归因于指南的不一致、医生的偏好、技术的缺乏以及不同的财务激励措施。低分割放疗使用的不必要差异对患者和医疗保健系统的成本都有巨大的影响。这给患者带来了不必要的负担，也没有充分利用稀缺的医疗资源。临床医生、患者、医疗保健提供者和政策制定者需要共同努力，减少实践中的不必要差异。这将提高患者和更广泛的医疗保健系统层面的护理质量。
